Table 3.

Univariate analysis

	Univariate analysis
	B	SE	HR (95% CI upper, lower)		p value
Age
Per year, continuous	0.012	0.006	1.012	1.000, 1.023	0.044
< 60 vs. ≥ 60	0.317	0.124	1.373	1.077, 1.750	0.011
< 70 vs. ≥ 70	0.745	0.183	2.107	1.471, 3.019	< 0.001
Menopausal status
Pre- vs. post-menopause	0.041	0.127	1.042	0.812, 1.337	0.746
T stage
T1 vs. T2-4	0.950	0.162	2.586	1.884, 3.552	< 0.001
N sage
N0 vs. N1-3	0.893	0.125	2.444	1.912, 3.123	< 0.001
Pathological tumor size
≤ 1 cm vs. > 1 cm	0.383	0.142	1.467	1.110, 1.938	0.007
Pathological lymph node metastasis
0 vs. 1–3 lymph nodes involved	0.429	0.145	1.536	1.156, 2.043	0.003
0 vs. ≥ 4 lymph nodes involved	1.152	0.149	3.164	2.365, 4.233	< 0.001
pN0 vs. pN +	0.715	0.121	2.044	1.611, 2.594	< 0.001
Grade
Grade 1 vs. 2	− 0.085	0.224	0.918	0.592, 1.424	0.703
Grade 1 vs. 3	− 0.036	0.213	0.964	0.635	0.865
ER status
Negative vs. positive	− 0.104	0.123	0.901	0.708, 1.146	0.396
HER2 status
IHC 3 + vs. 2 + FISH +	− 0.023	0.180	0.977	0.687, 1.389	0.896
IHC 3 + vs. FISH +	0.321	0.360	1.378	0.681, 2.790	0.373
Surgery (type)
Partial vs. total mastectomy	0.486	0.123	1.626	1.278, 2.070	< 0.001
Preoperative systemic therapy
No vs. Yes	0.409	0.122	1.505	1.185, 1.912	0.001
CTx concurrent with TZM vs. sequential	0.196	0.425	1.217	0.529, 2.802	0.644
CTx concurrent with TZM vs. without CTx	− 9.998	230.841	0.000	0.000, inf	0.965
Postoperative systemic therapy
No vs. yes	− 1.956	0.504	0.141	0.053, 0.380	< 0.001
CTx concurrent with TZM vs. sequential	− 0.006	0.182	0.994	0.696, 1.419	0.974
CTx concurrent with TZM vs. without CTx	0.472	0.176	1.604	1.136, 2.263	0.007
Chemotherapy
No vs. yes (pre and/or postoperative)	− 0.380	0.206	0.684	0.457, .025	0.066

B regression coefficient, SE regression coefficient of regression coefficient, HR hazard ratio; 95% CI 95% confidence interval